Partnership combines AbTherx's proprietary Atlas™ Long CDR3 Technology with GPCR Therapeutics' deep expertise in GPCR biology to discover and develop antibodies for novel targets MOUNTAIN VIEW, ...
Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies -- Kainova Therapeutics rebrand reflects expanding capabilities powering next stage of ...
The collaboration will leverage Abalone Bio’s Functional Antibody Selection Technology platform for an undisclosed ...
This comprehensive platform encompasses 59 GPCR protein families, 175 GPCR protein targets, and addresses 444 known indications. SentinusAI's ability to efficiently screen all extracellular epitopes ...
MarketBeat on MSN
AI Pharma: 2 Paths to AI-Powered Drug Investment
The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence ...
Domain Therapeutics becomes Kainova Therapeutics and advances its clinical pipeline of GPCR-modulating therapies: Montreal, Canada Tuesday, January 13, 2026, 18:00 Hrs [IST] Kaino ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results